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Background: Cluster headache (CH) is considered to be a catastrophic disease presenting
the most severe human pain condition. Available pharmacological treatments are hampered
by unwanted side effects, and there is an urgent need for non-pharmacological treatment
alternatives. We present a novel therapeutic approach for chronic CH, having evolved from
an episodic CH, using a non-invasive percutaneous bioelectric current stimulation (PBCS),
which generates static electric fields in the range of the naturally occurring electric potentials.
Patients and Methods: This study employed a retrospective data analysis of 20 cases of
chronic cluster headache (CCH) patients, four of those having had cluster-related surgery
(SPG, ONS). All patients were treated with PBCS between 2014 and 2018. Data of these
patients were analyzed with respect to frequency of CH attacks and triptan application and
followed up for one (20 cases) or two (12 cases) years.
Results: Four weeks after the first PBCS treatment, cluster headache attacks were reduced
from 2.8 to 1.7 per day and triptan application decreased from 2.5 to 1.5 times/day. Six non-
responders, 4 of which had pre-CH surgery, did not show any reaction to PBCS, while 14
responders improved within 4 weeks from 2.2 to 0.7 attacks/day and 2.0 to 0.4 triptan
applications/day. A 50% or greater reduction of attack frequency was observed in 10 patients
after 4 weeks and in 11 patients after 12 weeks. One year after the first treatment, 13/20
patients experienced a reduction of attack frequency of 50% or more, while remarkably 10
patients were completely free of attack. After 2 years, 8 of 12 patients experienced a
reduction of attack frequency of 50% or more and 7 of those were completely symptom-
free. No serious adverse effects were observed.
Conclusion: PBCS is a promising transformative treatment approach for CCH patients.
Drug consumption was reduced significantly, and the CCH may revert back to an episodic
cluster headache with increasingly long times of remission. Responders can be clearly
differentiated from non-responders. The data support the need for randomized controlled
trials.
Keywords: chronic cluster headache, bioelectric current, pain, direct current
Introduction
Cluster headache (CH) is regarded as a rare, but catastrophic, most severe pain
disorder. The prevalence of CH is estimated in a wide range between 7 and 160
patients per 100.000 (1:1000 as a rule of thumb, so in Germany 5600 to 95,200, and
in the US about 500.000 patients are affected).1,2 It is characterized by unilateral
headache attacks lasting 15–180 mins, which occur on average 2–3 times a day. The
pain is localized around the eye and can radiate to the upper jaw, temples, and
Correspondence: Albrecht Molsberger
Fax +49 211 86688 18
Email albrechtmolsberger@mac.com
Journal of Pain Research Dovepress
open access to scientific and medical research
Open Access Full Text Article
submit your manuscript | www.dovepress.com Journal of Pain Research 2020:13 817–828 817
http://doi.org/10.2147/JPR.S242093
DovePress © 2020 Molsberger and McCaig. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.
com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By
accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly
attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
 
Jo
ur
na
l o
f P
ai
n 
Re
se
ar
ch
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
87
.1
15
.7
1.
69
 o
n 
03
-J
un
-2
02
0
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Figure 1 Continued.
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Figure 1 X axis = no. of days of follow up; y axis = no. of attacks a day. Red bars = no. of attacks a day; blue dotted line = 7-day moving average. Green label = no. of PBCS
treatments at this time point. Patient 15–20 discontinued headache diary, they were followed up by telephone interview and last value carried over method was used to
impute missing data.
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forehead and back of the head. The pain is usually per-
ceived as burning and stabbing and has a devastating
character.1,2 In the episodic form of CH, headache attacks
are more frequent in spring and autumn, with pain-free
intervals in between. About 10–15% of CH patients suffer
from a chronic form (CCH) with attacks occurring for 1
year or longer without remission or with remission periods
lasting less than 3 months. Chronic forms are further
subdivided as a primary CCH which is chronic from the
very first onset of the disease and an “evolved” form,
which evolves from an episodic form.3 Acute therapy
consists of the administration of oxygen inhalation and
triptan nasal sprays or injections. Verapamil, topiramate
and lithium are usually given as a prophylactic treatment.4
Due to the intensive treatment, the annual costs are
between 5.000 and 20.000 Euros per patient.2
Available pharmacological treatments are hampered by
unwanted side effects and there is an urgent need for new
non-pharmacological treatment alternatives5–9 There are
interesting new developments in electronic stimulation
methods for neuromodulation. These include occipital
nerve stimulation (ONS) (evidence level IV), microstimu-
lation of the ganglion sphenopalatine (SPG) and noninva-
sive vagus stimulation (nVNS) (the latter two with
evidence Level 2).10,11 All these forms of stimulation
have in common that they work with frequencies, pulse
widths and currents in the milliampere range, as they have
been used for decades in transcutaneous nerve stimulation.
The common rationale is to interrupt the afferent pathway
by overriding the electrical capacity of nerves to generate
further action potentials. In contrast to these neurostimu-
lator devices, we present here a novel approach that uses
percutaneous bioelectric direct current stimulation
(PBCS). This electrical stimulation modulates tissue-spe-
cific small electric fields like transepithelial potentials thus
interacting with charged ions and peptides. PBCS was
originally developed for locomotive problems; however,
incidentally we observed a clinical effect in Cluster head-
ache. In the following, we present a retrospective analysis
of CCH patients having been treated with remarkable
success by this new treatment.12
Materials and Methods
Patient Characteristics
During the preceding 4 years, patients with episodic and
chronic cluster headache (CCH) were treated with percu-
taneous bioelectric current stimulation (PBCS) in our pain
clinic.12 For this study we performed a retrospective data
analysis of all patients meeting the following inclusion
criteria: informed consent; chronic cluster headache,
which had evolved from episodic cluster headache; at
least 11 months of continues CH prior to PBCS treatment;
a minimum of 3 attacks per week, triptan and/or oxygen
being effective for acute treatment. Patients were not
actively recruited; however, they reported for therapy
after they heard in German social media (CH patient for-
ums, self-help groups) from other patients about PBCS.
All patients were asked to fill in a headache diary begin-
ning at least 2 weeks before the first treatment and con-
tinuing throughout the treatment and follow up time up to
2 years. Typical CH characteristics had to be reported,
including attack frequency, pain severity on a numeric
rating scale (NRS) from 0=no pain at all to 10 = unbear-
able pain, duration of attack and medication consumption.
Data were collected during clinical visits and by email and
telephone interviews.
Treatment Characteristics and Outcome
Assessment
The PBCS treatment system has been approved and certified
for pain treatment by a notified body of the European
Commission (CE0482). A mobile, hand-held electroceutical
smart device, based on a microcontroller, an analog frontend
and a battery generates DC electric fields (EFs) mimicking
and modulating those electrical signals, which are observed
in inflammation, wound healing and tissue regeneration. A
large body of evidence exists, showing that these small DC
EFs provide pivotal directional cues for the migration of
inflammatory cells (monocytes, macrophages), epithelial
cells, fibroblasts and nerve cells13–17 Extensive technical
details as well as the physiological rational of this novel
treatment has been published recently.12
Patients received PBCS treatments on a weekly or
biweekly basis. Insertion points usually were located
within these topographical areas: below the maxilla,
1–4 cm lateral to the ala of the nose; the medial end of
the eyebrow; the middle of eyebrow; on the forehead 1 cm
above the middle of the eyebrow; at the temporal region;
at the vertex 1–2 cm lateral to the midline; the occipital
region above the major occipital nerve. To precisely locate
the points selected for stimulation, patients were asked to
indicate the typical painful areas appearing during an
attack, which were confirmed by applying pressure with
a 6 mm thick rounded metal probe, similar to a “follow the
Molsberger and McCaig Dovepress
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pain” strategy as it is used for botulinum toxin injection or
acupuncture in migraine.18,19 Then, an unsiliconised acu-
puncture needle (0,25 in diameter) was inserted carefully
until the patient felt a sharp increase of pain. Secondly, the
needle was redrawn for a few millimeters, just enough to
avoid further eliciting pain. Depending on the size of the
area to be treated up to 9 needle probes were inserted,
usually 1 probe per square centimeter. In these cases, the
depth of insertion was defined by the location of the area
to be treated and ranged from 0.5 cm (eg, temporal region)
to 4 cm (below the maxilla and arcus zygomaticus). A
conductive skin pad was placed on the ipsilateral upper
arm above the musculus deltoideus. The anodal output of
the digital stimulator device was then connected to the
skin pad and the cathodal output to the needle probes.
Finally, an undulating direct current in the range of
15–100 µA per needle was applied for 30 mins.
To assess the effectiveness of PBCS we measured
reductions in the number of attacks and in the consump-
tion of triptans per day in comparison to baseline. Adverse
events were collected from patients’ notes. As a retro-
spective outcome chart analysis of a certified medical
device treatment having been used for individual curative
treatments, the German medical association stated that an
ethics committee approval was not required.
Results
Twenty patients, 5 female, 15 male, mean age 45 years,
suffering from CCH, all evolved from ECH, were treated
with PBCS. Four of the CCH patients had a history of
several cluster-related surgeries including the implantation
of an electrical stimulator of the ganglion sphenopalatine
(SPG stimulation) and/or of the nervus occipitalis major
(ONS); one patient had received six operations at the
corresponding nasal sinuses. At the time of the start of
PBCS therapy, none of the stimulators was being used
either because they had not shown any relevant effect on
the patient in the past (SPG), or the effect has vanished
over time (ONS). Since this is a first observational study,
the following description includes those pre-operated
patients.
The mean duration of CH was 13 years, first as an
episodic form, then during the last 6 years changing into a
chronic CH form. In 10 patients the pain was on the right
and in 8 patients on the left side; in two patients the pain
changed from one side to the other. All patients had a
history of the typical acute (triptans, inhalation of oxygen)
and prophylactic treatments (verapamil, lithium,
topiramate). The diagnosis was confirmed by at least one
neurologist, six patients having been treated in an ambu-
latory, six in a stationary specialized headache center and
five in both. All patients had tried cortisone treatment
without lasting effect. Before the beginning of the PBCS
treatment, 11 patients took verapamil (mean daily dosage
585 mg), while nine patients had stopped the prophylactic
verapamil treatment because of insufficient effect or
unwanted side effects. Two patients only used oxygen for
the acute treatment, two patients had replaced triptans
because of unbearable side effects – one took metamizole
for more than 10 years, the other Ergotamine for the last
15 years (individual patient data are presented in Table 1).
With the above prophylactic treatment, the typical patient
suffered from 2.8/2.3 (mean/median) attacks per day with
a pain severity of 6.7/6.7 and would take 2.5/2.3 triptans
(nasal application or injections) as an acute treatment (all
values at baseline, see Table 1). She/He received 3.9/4
PBCS treatments within 2 weeks. Four and (12) weeks
after the first treatment, the number of attacks per day had
reduced to 1.7/0.8 (1.4/0.6), the pain severity to 3.1/2.2
(3.1/2.4) and the triptan intake to 1.5/0.3 (1.4/0.4)
(Table 1, Figure 2). A 50% or more reduction of pain
frequency was observed in 10 patients after four and in
11 patients after 12 weeks of stimulation (Table 1).
All 20 patients could be followed up for 12 months.
During this time span, 12 patients showed a recurrence of
the attacks, which were stopped by one or more courses of
PBCS treatment (Table 1, PBCS treatments, Figure 1). At
12 months follow up 13 patients experienced a reduction
of attack frequency of 50% or more, 10 of those being
symptom-free without any attacks. After 24 months eight
patients experienced a reduction of attack frequency of
50% or more, 7 of those being symptom-free (Table 1,
last two rows). No serious adverse effects were observed.
Of the six patients who showed no response to PBCS
therapy, four belonged to the group of pre-operated
patients and one other patient had developed CH after a
suicide attempt with Herphonal. Overall, the non-respon-
ders compared to the responders had higher baseline
values for attack rate (4.3 versus 2.2 (mean)), pain severity
(7.6 versus 6.3) and triptan consumption (3.8 versus 2.0).
In a stratified evaluation, in non-responders, there was no
change in the number of attacks (4.3/4.2 (mean)) and
triptan consumption (3.8/4.1 within the first 4 weeks. In
the responder group, the number of attacks was reduced
from 2.2 to 0.7 (mean) and the triptan consumption from
2.0 to 0.4 within the first 4 weeks.
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Below, we describe six patient cases (patient 2, 4. 7,
12, 14, 15) illustrating five typical patterns of reaction to
the PBCS treatment (Figure 1). As supplementary mate-
rial, four video testimonials (patient 7, 10, 11, 12) and
patterns of all patients are provided. Video 2 also shows
the device and demonstrates the treatment.
No Reaction to PBCS – Complete Non-
Responders
Cases 15–20
Example Case 15
Fifty-three-year-old female patient with a history of 7
years of CH, the last 1.5 years being chronic. CH started
with an overdose of Herphonal immediately after an
attempted suicide due to depression. The current therapy
consisted of Sumatriptan 2 tablets daily, oxygen inhalation
and Verapamil 480 mg per day. Four PBCS therapies
within 9 days showed no effect at all in terms of attack
rate or frequency, so the therapy attempt was terminated.
In the following 12 months, further therapeutic trials with
cortisone, lithium and topiramate were discontinued due to
intolerance. Due to the severity of the disease, several
applications for retirement have been submitted.
Long-Lasting Remissions
Cases 1, 2, 3
Example Case 2: 25-year-old male patient with a history of 6
years of CH, the last 1.5 years being chronic. In the past
Verapamil 240 mg had to be stopped because of bradycardia
and attacks could have been stopped only with cortisone
courses. Before the treatment he had suffered from 1.5 attacks
per day, being treated with Triptan nasal application and oxy-
gen inhalation. The patient received 3 PBCS treatments within
7 days. Among them, the number of attacks and pain intensity
decreased slightly. However, without any further therapy 2
weeks after the last PBCS treatment, the attacks were comple-
tely suspended. The patient has now been symptom-free for
more than 1 year, showing long-lasting remission.
A B
c
Figure 2 (A) Attack frequency, (B) pain level, (C) triptane intake. Mean values for all patients, responders and non-responders, respectively.
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Long-Lasting Remissions with Easier
Recurrent Episodes
Cases 4, 5, 6, 7, 8, 9, 10
Example Case 4
Sixty-nine-year-old male patient with a history of 20 years
of CH, the last 19 years being chronic. Besides cluster
attacks every other day, he had suffered from a 24 hr con-
comitant level 4 pain homolateral beneath the eye in the
region of the upper jaw. At the beginning he received 4
PBCS treatments with subsequent complete pain relief of
the concomitant pain and only very rare attacks; three
months later and after 6 months he needed two more treat-
ment series with 3 sessions. During the second year, he
needed only one treatment to stay completely free of pain.
Example Case 7
Thirty-two-year-old male patient with a history of 11 years
of CH, the last 10 years being chronic. In the beginning,
verapamil and lithium helped well, but were discontinued
due to decreasing effect and concentration problems. Before
PBCS treatment began, the patient suffered from one attack
per day of pain level 8, each of which he treated with triptan
nasal sprays, since the beneficial effect of oxygen inhala-
tions had decreased last year. The patient received 4 PBCS
treatments within 11 days. After the third treatment attacks
were reduced significantly for 6 months, followed by an
episode of light attacks, for which the patient did not seek
treatment. Another 7 months later, a second episode of
attacks occurred, again with somewhat less pain. After 3
further PBCS treatments, the patient was symptom-free.
Long-Lasting Remissions with More Severe
Recurrent Episodes
Cases 11, 12, 13
Example Case 12
This is an example of a lengthy and ultimately successful
course of PBCS therapy in a 59-year-old patientwith a history
of 20 years of CH, the last 10 years being chronic. In the first
years, the cluster was successfully treated with oxygen, trip-
tans and verapamil. With decreasing effect the therapy was
changed to 2mg Cafergot daily, 15 years ago. Until 6 years
ago she was completely pain-free; since then the Cafergot
therapy lost effect and she again suffered 4 attacks a day.
Twice the patient tried to have an ergotamine withdrawal
under cortisone protection in specialized headache clinics.
The attempt failed both times because the attacks increased
unbearably in frequency and pain intensity even under
cortisone protection and additionally an ergotamine withdra-
wal headache occurred. Due to the frustrating therapy results,
the patient was ultimately advised to implant an SPG stimu-
lator. When she introduced herself for PBCS therapy, she
suffered from daily attacks of pain level 7. Within 1 week, 3
PBCS stimulationswere performed, resulting in the complete
suspension of cluster attacks. Afterwards, the ergotamine
could be reduced to zero within 2 weeks under further 3
PBCS stimulations to treat the ergotamine withdrawal head-
ache. Interestingly without ergotamine therapy, CH attacks
occurred again, albeit with a 50% reduction in frequency and
painfulness. Another 3 treatments and a subsequent week-
long cortisone treatment with 60 mg prednisolone showed a
different effect than in the past and in combination with 2
further PBCS therapies the patient was again completely
painless in the following 6 weeks. Two more exacerbations
followed, which were treated with 2 PBCS therapies each.
Since then, the patient has been completely symptom-free
without taking any medication (13 months).
Minor, Not Lasting Improvement
Case 14
Example: 62-year-old male patient with a history of 11
years of CH. At first, the CH was right-sided, but years
ago the location switched to the left side and has been
chronic ever since. Until recently he took 720mg verapamil
but this was no longer tolerated and he now treated every
attack exclusively with triptan injections and oxygen. When
he started the PBCS treatment he had two to four attacks at
night, the main pain being located behind the left eye,
radiating into the lower jaw. Already after the second
PBCS therapy attack frequency was reduced to only one
attack per night. Also, the pain decreased so that he did not
need any acute medication anymore. After the third treat-
ment. the CH changed to the right side. After three further
treatments, he was completely pain-free for 3 months. Then,
the CH started again. This time, after his previous positive
experiences with the PBCS therapy, the patient was highly
motivated to be treated again. Eighteen further treatments
improved the frequency of attacks, also the intensity of
pain, but overall the clinical result was not sufficiently
satisfactory so that the treatment attempt was terminated
without lasting success.
Discussion
In this retrospective analysis, with a considerably long follow
up period of up to 2 years, we have presented clinical cases of
severe CCH, evolved from ECH, with the majority having
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benefited to a great extent from the new PBCS treatment
approach, many achieving prolonged remission from a dis-
ease, which until now has been regarded as the most painful
and incurable pain problem. Acute use of triptan medication
also was significantly reduced following PBCS. No severe
adverse events were observed. Compared to SPG, ONS or
nVNS, which are primarily used on demand for the treatment
of acute attacks, our data suggest, that PBCS stimulation has
a strong prophylactic, long-term effect. Whether a PBCS
therapy is helpful for a patient is apparent already within
the first 2 weeks after a maximum of 4 treatments, as the
following comparison between responders and non-respon-
ders suggests.
Six of 20 patients showed no response to PBCS treat-
ments. For clinical use and for future studies it would be
important to identify such non-responders in advance.
According to our data – despite all reservations due to
the small number of patients – a CH-related previous
operation, a higher number of attacks and a higher con-
sumption of triptan can be considered as prognostically
unfavorable. This almost binary distinction between non-
responders and responders is reflected in the clear differ-
ences between all mean and median values, as well as in a
separate analysis of both groups. Here it can be seen that
the characteristic values of the non-responders do not
change. In responders, on the other hand, within 4 weeks
after the first treatment the number of attacks is reduced by
more than 60% and the triptan consumption by 80%.
Similar to other pharmacological (Botox injection, nasal
Lidocaine application, occipital Cortisone injections) or elec-
trical stimulations of the occipital nerve or the ganglion
sphenopalatine the stimulating probes are placed precisely
at the patient’s painful areas of the three trigeminal nerves,
and in the vicinity of the ganglion sphenopalatine and the
nervus occipitalis major.4,7-9 In distinction to other electrical
stimulations, which use high intensity and frequency to
reduce afferent transduction of pain signals or use high-
intensity direct currents for transcranial stimulation, PBCS
stimulation uses small direct currents in the range of those
found naturally in the body, such as those driven across
epithelial (and endothelial) tissues by the transepithelial (or
endothelial) potential difference (TEP).6 In PBCS currents of
between 15 and 100 µA are applied for 30 mins and since
human tissue has a resistance of around 500 Ω these will
correspond to voltages of around 7.5 – 50mV. Over a distance
of several mm, such a voltage drop has profound effects on
the behaviors of many cell types. These include fibroblasts,
epithelial cells, nerve cells, macrophages and monocytes,
which collectively are required to orchestrate the regenera-
tion of wounds. Such small electrical signals regulate and
direct cell migration, the release of neurotransmitters, cyto-
kines and several growth factors, the positioning and quantity
of surface receptors for such ligands and promote an anti-
inflammatory effect (buffering of acidosis and disintegration
of charged pro-inflammatory peptides)13–17 PBCS is there-
fore likely to induce the release and accumulation of a com-
plex cocktail of molecules in the perivascular spaces of
sensory nerves.
How might relatively short bursts of small electrical
signals alleviate CH? One possibility could involve the elec-
trical regulation of mast cells. Mast cell progenitors home in
on and increase in both the skin and the adventitia around the
trigeminal nerve during CH attacks.20,21 They are present in
elevated numbers at electroacupuncture acupoints where
they release histamine, adenosine and cytokines amongst a
cocktail of molecules.22 This mast cell degranulation is evi-
dent also in CH. Chemoattraction involving CXCL2 gradi-
ents and CXCR2 receptors present in mast cell progenitors
promotes further mast cell accumulation at inflammation
sites, for example, during CH. Interestingly electric fields
(EF) enhance CXCR2 expression in vascular endothelial
cells.23 Although a number of blood-derived cells show
directed cell migration in response to small electrical fields
(macrophages, monocytes, neutrophils and T cells24,25),
whether mast cells are electrosensitive and might accumulate
focally at stimulation sites, is not known but is testable.
However, if the EFs established by PBCS needles directed
mast cell migration and regulated cytokine secretion and
receptor expression as occurs in many other cell types, a
mast cell-based explanation of the remarkable efficacy of
PBCS in alleviating CH may emerge. Why such short peri-
ods of electrical stimulation have such long-lasting effects in
abolishing CH remains unclear.
Typically, the evolved chronic cluster develops from the
episodic form, as the painless intervals between cluster
attack times become shorter and shorter until the cluster
finally exists for more than 9 months per year. Unlike
primary CCHs, evolved CCHs can also experience pain-
free months from time to time. Against this background, the
effect of PBCS therapy can be interpreted in such a way
that an evolved chronic cluster is first returned to an episo-
dic form followed by ever-increasing pain-free intervals.
Limitations
This is a retrospective evaluation of CCH patients treated
at our Headache Centre during the last 4 years. Patient
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progressions were described as we observed them under
real clinical conditions, a prospective formalization of
measurement times and therapy progressions did not take
place, likewise naturally no sham or placebo control ther-
apy. In this respect, no efficacy analysis can be derived
from the available data as in a controlled study nor can we
control any placebo effect. However, the same response
patterns across different patients (eg, patient pattern 4, 7)
and an effect that persists for many months in some
patients (eg, patient 1, 2) strongly indicate an intrinsic
effect of PBCS therapy. For these reasons, we here limit
ourselves to purely descriptive statistics. From what level
of pain an attack is evaluated and documented as such is a
very subjective decision. However, in so-called “knock-
knock attacks”, in contrast to full-blown attacks, no triptan
is taken, so the triptan intake/day helps to differentiate
here (see, for example, patient 11). Even if we have not
seen any serious undesirable effects, we cannot make a
statistically based statement on possible rare side effects
due to the small number of cases. However, the safety of
the therapy is supported by the fact that the electrical
currents used to stimulate the “identified source of the
pain” are in the low physiological range and are thus far
below the established and clinically classified safe levels
delivered by frequency-based stimulation therapies.
Conclusion
These encouraging cases indicate that PBCS is a promis-
ing possibly transformative prophylactic treatment
approach for CCH patients. With PBCS treatment, it
could be observed that the CCH may revert back to an
episodic Cluster headache with increasing pain-free inter-
vals. Within the first four treatments, responders can be
differentiated from non-responders and show a 60% reduc-
tion in CH attacks and 80% reduction in triptan intake.
The data support the urgent need for randomized con-
trolled trials for PBCS and should serve as a basis to
develop the best-suited inclusion, exclusion criteria, pri-
mary endpoints, measurement intervals, and size of such a
study.
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